The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Busulfex     1,4- bis(methylsulfonyloxy)butane

Synonyms: Myelosan, busulfan, Busulphan, Mylecytan, Myleran, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Myleran


Psychiatry related information on Myleran


High impact information on Myleran


Chemical compound and disease context of Myleran


Biological context of Myleran

  • Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia [14].
  • Dose (milligrams per kilogram), peak plasma level, and area under the curve (AUC) were all higher in 12 children treated with 150 mg/m2 busulfan than in 9 children treated with 4 mg/kg [14].
  • We applied a well-tolerated, nonirradiation-based, allogeneic transplantation protocol using nonmyeloablative preconditioning (low-dose busulfan) and costimulation blockade (CTLA4-Ig and anti-CD40L) to produce mixed chimerism and transplantation tolerance to fully major histocompatibility complex-mismatched donor marrow [15].
  • Once engraftment occurred, whether patients had or had not received Busulfan in the conditioning regimen did not influence the kinetics and quality of T-cell function development [16].
  • A complete cytogenetic response was induced in seven (8.8%) of 80 patients treated with IFN-alpha and two (2.5%) of 79 patients treated with busulfan, and a partial cytogenetic response was 7.5% (6/80) and 2.5% (2/79), respectively [17].

Anatomical context of Myleran

  • A single injection of Myleran reduced the pluripotent hematopoietic stem cell, i.e., colony forming unit(s) (CFU), and the erythropoietin-responsive cell (ERC) in polycythemic mice to around 0.5% that of the controls [18].
  • After high-dose chemotherapy in 14 of the patients (busulphan and cyclophosphamide), these cells were used to augment autologous bone-marrow rescue and post-transplant filgrastim treatment [19].
  • To test this possibility 587 patients with CML in chronic phase were randomly allocated to receive lymphoblastoid cell-line interferon-alpha n1 (IFN-alpha, n = 293) or chemotherapy with busulphan or hydroxyurea (no IFN-alpha, n = 294) as maintenance after initial induction treatment with cytotoxic drugs [20].
  • The rate of decrease of the elevated leukocyte count was more rapid with DBM, but prolonged disease control off treatment occurred in only three of 14 cases as opposed to nine of fifteen busulfan-treated patients who required a median delay of 12 mo before maintenance could be initiated [21].
  • Despite slower early reconstitution after lower doses of busulfan, donor lymphocytes exceeded 90% to 95% by 90 to 120 days after HCT in all mice given at least 20 mg/kg [22].

Associations of Myleran with other chemical compounds


Gene context of Myleran


Analytical, diagnostic and therapeutic context of Myleran


  1. Survival of patients with polycythemia vera on busulfan or 32P. Mathé, G. N. Engl. J. Med. (1978) [Pubmed]
  2. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. Santos, G.W., Tutschka, P.J., Brookmeyer, R., Saral, R., Beschorner, W.E., Bias, W.B., Braine, H.G., Burns, W.H., Elfenbein, G.J., Kaizer, H. N. Engl. J. Med. (1983) [Pubmed]
  3. Endocardial fibrosis following busulfan treatment. Weinberger, A., Pinkhas, J., Sandbank, U., Shaklai, M., de Vries, A. JAMA (1975) [Pubmed]
  4. Sicca syndrome in a patient with toxic reaction to busulfan. Sidi, Y., Douer, D., Pinkhas, J. JAMA (1977) [Pubmed]
  5. Effect of busulfan on oncornavirus-like activity in platelets and chromosomes in polycythemia vera and essential thrombocythemia. Brodsky, I., Fuscaldo, A.A., Erlick, B.J., Fuscaldo, K.E. J. Natl. Cancer Inst. (1977) [Pubmed]
  6. Etoposide in combination with cyclophosphamide and total body irradiation or busulfan as conditioning for marrow transplantation in adults and children. Spitzer, T.R., Peters, C., Ortlieb, M., Tefft, M.C., Torrisi, J., Cahill, R., Gadner, H., Urban, C., Deeg, H.J. Int. J. Radiat. Oncol. Biol. Phys. (1994) [Pubmed]
  7. Cytogenetic effects of myleran in vivo on bone-marrow cells from male mice. Léonard, A., Léonard, E.D. Mutat. Res. (1978) [Pubmed]
  8. In vivo distinction between a target cell for Friend virus (FVP) and murine hematopoietic stem cells. Nasrallah, A.G., McGarry, M.P. J. Natl. Cancer Inst. (1976) [Pubmed]
  9. Oesophageal varices associated with busulphan-thioguanine combination therapy for chronic myeloid leukaemia. Key, N.S., Kelly, P.M., Emerson, P.M., Chapman, R.W., Allan, N.C., McGee, J.O. Lancet (1987) [Pubmed]
  10. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Hehlmann, R., Heimpel, H., Hasford, J., Kolb, H.J., Pralle, H., Hossfeld, D.K., Queisser, W., Löffler, H., Hochhaus, A., Heinze, B. Blood (1994) [Pubmed]
  11. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Or, R., Shapira, M.Y., Resnick, I., Amar, A., Ackerstein, A., Samuel, S., Aker, M., Naparstek, E., Nagler, A., Slavin, S. Blood (2003) [Pubmed]
  12. Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Dimopoulos, M.A., Alexanian, R., Przepiorka, D., Hester, J., Andersson, B., Giralt, S., Mehra, R., van Besien, K., Delasalle, K.B., Reading, C. Blood (1993) [Pubmed]
  13. Acute graft-versus-host disease prophylaxis with methotrexate and cyclosporine after busulfan and cyclophosphamide in patients with hematologic malignancies. von Bueltzingsloewen, A., Belanger, R., Perreault, C., Bonny, Y., Roy, D.C., Lalonde, Y., Boileau, J., Kassis, J., Lavallee, R., Lacombe, M. Blood (1993) [Pubmed]
  14. Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia. Shaw, P.J., Scharping, C.E., Brian, R.J., Earl, J.W. Blood (1994) [Pubmed]
  15. A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation. Kean, L.S., Durham, M.M., Adams, A.B., Hsu, L.L., Perry, J.R., Dillehay, D., Pearson, T.C., Waller, E.K., Larsen, C.P., Archer, D.R. Blood (2002) [Pubmed]
  16. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. Haddad, E., Landais, P., Friedrich, W., Gerritsen, B., Cavazzana-Calvo, M., Morgan, G., Bertrand, Y., Fasth, A., Porta, F., Cant, A., Espanol, T., Müller, S., Veys, P., Vossen, J., Fischer, A. Blood (1998) [Pubmed]
  17. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Ohnishi, K., Ohno, R., Tomonaga, M., Kamada, N., Onozawa, K., Kuramoto, A., Dohy, H., Mizoguchi, H., Miyawaki, S., Tsubaki, K. Blood (1995) [Pubmed]
  18. Target cell of the polycythemia-inducing Friend virus: studies with myleran. Fredrickson, T., Tambourin, P., Wendling, F., Jasmin, C., Smajda, F. J. Natl. Cancer Inst. (1975) [Pubmed]
  19. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Sheridan, W.P., Begley, C.G., Juttner, C.A., Szer, J., To, L.B., Maher, D., McGrath, K.M., Morstyn, G., Fox, R.M. Lancet (1992) [Pubmed]
  20. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Allan, N.C., Richards, S.M., Shepherd, P.C. Lancet (1995) [Pubmed]
  21. Dibromomannitol in the treatment of chronic granulocytic leukemia: a prospective randomized comparison with busulfan. Canellos, G.P., Young, R.C., Neiman, P.E., DeVita, V.T. Blood (1975) [Pubmed]
  22. Lymphoid reconstitution after transplantation of congenic hematopoietic cells in busulfan-treated mice. Yeager, A.M., Shinn, C., Pardoll, D.M. Blood (1991) [Pubmed]
  23. Clobazam for seizure prophylaxis during busulfan chemotherapy. Schwarer, A.P., Opat, S.S., Watson, A.L., Cole-Sinclair, M.F. Lancet (1995) [Pubmed]
  24. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Locatelli, F., Nöllke, P., Zecca, M., Korthof, E., Lanino, E., Peters, C., Pession, A., Kabisch, H., Uderzo, C., Bonfim, C.S., Bader, P., Dilloo, D., Stary, J., Fischer, A., Révész, T., Führer, M., Hasle, H., Trebo, M., van den Heuvel-Eibrink, M.M., Fenu, S., Strahm, B., Giorgiani, G., Bonora, M.R., Duffner, U., Niemeyer, C.M. Blood (2005) [Pubmed]
  25. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Barker, J.N., Weisdorf, D.J., DeFor, T.E., Blazar, B.R., Miller, J.S., Wagner, J.E. Blood (2003) [Pubmed]
  26. In vivo erythropoietin requirements of regenerating erythroid progenitors (BFU-e, CFU-e) in bone marrow of mice. Udupa, K.B., Reissmann, K.R. Blood (1979) [Pubmed]
  27. Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Czerwinski, M., Gibbs, J.P., Slattery, J.T. Drug Metab. Dispos. (1996) [Pubmed]
  28. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Srivastava, A., Poonkuzhali, B., Shaji, R.V., George, B., Mathews, V., Chandy, M., Krishnamoorthy, R. Blood (2004) [Pubmed]
  29. Hematopoietic cell transplantation in the twitcher mouse. The effects of pretransplant conditioning with graded doses of busulfan. Yeager, A.M., Shinn, C., Shinohara, M., Pardoll, D.M. Transplantation (1993) [Pubmed]
  30. Identification, immunolocalization, regulation, and postnatal development of the lipocalin EP17 (epididymal protein of 17 kilodaltons) in the mouse and rat epididymis. Fouchécourt, S., Lareyre, J.J., Chaurand, P., DaGue, B.B., Suzuki, K., Ong, D.E., Olson, G.E., Matusik, R.J., Caprioli, R.M., Orgebin-Crist, M.C. Endocrinology (2003) [Pubmed]
  31. Murine male germ cell apoptosis induced by busulfan treatment correlates with loss of c-kit-expression in a Fas/FasL- and p53-independent manner. Choi, Y.J., Ok, D.W., Kwon, D.N., Chung, J.I., Kim, H.C., Yeo, S.M., Kim, T., Seo, H.G., Kim, J.H. FEBS Lett. (2004) [Pubmed]
  32. Splenectomy in chronic myeloid leukemia. Wolf, D.J., Silver, R.T., Coleman, M. Ann. Intern. Med. (1978) [Pubmed]
  33. The number of donor CD3(+) cells is the most important factor for graft failure after allogeneic transplantation of CD34(+) selected cells from peripheral blood from HLA-identical siblings. Urbano-Ispizua, A., Rozman, C., Pimentel, P., Solano, C., de la Rubia, J., Brunet, S., Pérez-Oteiza, J., Ferrá, C., Zuazu, J., Caballero, D., Carvalhais, A., Díez, J.L., Espigado, I., Martínez, C., Campilho, F., Sanz, M.A., Sierra, J., García-Conde, J., Montserrat, E. Blood (2001) [Pubmed]
  34. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. Seger, R.A., Gungor, T., Belohradsky, B.H., Blanche, S., Bordigoni, P., Di Bartolomeo, P., Flood, T., Landais, P., Müller, S., Ozsahin, H., Passwell, J.H., Porta, F., Slavin, S., Wulffraat, N., Zintl, F., Nagler, A., Cant, A., Fischer, A. Blood (2002) [Pubmed]
  35. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Bearman, S.I. Blood (1995) [Pubmed]
  36. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Finazzi, G., Caruso, V., Marchioli, R., Capnist, G., Chisesi, T., Finelli, C., Gugliotta, L., Landolfi, R., Kutti, J., Gisslinger, H., Marilus, R., Patrono, C., Pogliani, E.M., Randi, M.L., Villegas, A., Tognoni, G., Barbui, T. Blood (2005) [Pubmed]
WikiGenes - Universities